Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Assets (2019 - 2025)

Avidity Biosciences (RNA) has disclosed Assets for 7 consecutive years, with $2.0 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Assets rose 25.2% year-over-year to $2.0 billion, compared with a TTM value of $2.0 billion through Dec 2025, up 25.2%, and an annual FY2025 reading of $2.0 billion, up 25.2% over the prior year.
  • Assets was $2.0 billion for Q4 2025 at Avidity Biosciences, up from $1.4 billion in the prior quarter.
  • Across five years, Assets topped out at $2.0 billion in Q4 2025 and bottomed at $290.5 million in Q2 2021.
  • Average Assets over 5 years is $802.5 million, with a median of $612.4 million recorded in 2023.
  • The sharpest move saw Assets fell 18.24% in 2021, then soared 148.81% in 2024.
  • Year by year, Assets stood at $427.6 million in 2021, then soared by 49.4% to $638.8 million in 2022, then decreased by 1.6% to $628.6 million in 2023, then skyrocketed by 148.81% to $1.6 billion in 2024, then grew by 25.2% to $2.0 billion in 2025.
  • Business Quant data shows Assets for RNA at $2.0 billion in Q4 2025, $1.4 billion in Q2 2025, and $1.5 billion in Q1 2025.